



Sanofi Ventures Leads \$17 Million Financing of Click Therapeutics

CAMBRIDGE, Mass. and NEW YORK - July 23, 2018 - [Click Therapeutics, Inc.](#) ("Click"), a leader in Digital Therapeutics™ solutions as prescription medical treatments, announces a \$17 million financing round led by Sanofi Ventures. Click will use this financing to continue advancing its proprietary platform and pipeline of prescription digital therapeutics to treat a wide range of diseases. Recent notes were converted to equity as part of the financing.

"We've evaluated many companies in this space, and we believe Click Therapeutics' mobile patient engagement platform positions the company to be a leader in the field of prescription digital therapeutics," said Bernard Davitian, SVP and Managing Director of Sanofi Ventures, who has joined Click's Board in conjunction with the financing. "Click's platform enables the company to target multiple indications efficiently and effectively, and we have invested with the intent of partnering across a variety of therapeutic areas. Sanofi Ventures is excited to join Click on this journey of building a new pillar of medicine."

In addition to Clickotine®, Click's commercial product for smoking cessation, the company is developing prescription digital therapeutics for the treatment of depression (CT-152), insomnia (CT-141), acute coronary syndrome (CT-111), and chronic pain (CT-130). Click will seek FDA clearance for these programs as class II medical devices with disease-specific treatment claims, to be prescribed by physicians and reimbursed by payers.

"The Click Therapeutics team is proud to partner with Sanofi Ventures to advance our pipeline and expand our product portfolio of prescription medical treatments," remarked David Benshoof Klein, Co-founder and CEO of Click. "As we announced last summer, in 2017 we expanded our collaboration with Magellan Health, Inc. to pursue regulatory clearance from the FDA for indication-specific prescription digital therapies, leveraging the industry-leading suite of intellectual property and data from Magellan's existing software as well as their vast coverage and reimbursement leadership. The addition of Sanofi as a strategic investor, and the closing of this financing, represent major steps forward for Click and for the field of software as prescription medical treatments. By connecting patients with cognitive and neurobehavioral interventions, our platform will bring clinically-validated digital therapeutic solutions into mainstream healthcare."

About Sanofi Ventures

Sanofi Ventures is the corporate venture capital arm of Sanofi. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. Among these areas are rare diseases, vaccines, potential cures in other core areas of Sanofi's business footprint, and digital health solutions. For more information, visit www.sanofiventures.com.

About Magellan Health

[Magellan Health, Inc.](#), a [Fortune 500 company](#), is a leader in managing the fastest growing, most complex areas of health, including special populations, complete pharmacy benefits and other specialty areas of healthcare. Magellan supports innovative ways of accessing better health through technology, while remaining focused on the critical personal relationships that are necessary to achieve a healthy, vibrant life. Magellan's customers include health plans and other managed care organizations, employers, labor unions, various military and governmental agencies and third-party administrators. For more information, visit MagellanHealth.com.

About Click Therapeutics

Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click's Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes. Following a groundbreaking clinical trial, Click's industry-leading smoking cessation program is

101 Avenue of the Americas, 8th Floor

New York, NY 10013

www.clicktherapeutics.com

The Leader in Digital Therapeutics™ Solutions



available nationwide through a wide variety of payers, providers, and employers. Click's lead prescription program is entering into a multi-center, randomized, controlled, parallel-group, phase III FDA registration trial for the treatment of Major Depressive Disorder in adults. For more information, visit ClickTherapeutics.com.

###

Company Contact

Sarah Jackson
Chief of Staff
sarah@clicktherapeutics.com

Media Contact

Stefanie Tuck
MacDougall Biomedical Communications
stuck@macbiocom.com
781-235-3060